Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Completed · Phase 4

Conditions studied: Chronic Plaque Psoriasis

In brief

A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Key facts

Study ID

NCT00493324

Run by

Astellas Pharma Inc

People needed

43

Starts

2007-07-01

Expected to finish

2008-07-01

Last updated by the study team

2012-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has chronic plaque psoriasis
• Subject has at least 5% body surface area affected with psoriasis

You may not qualify if…

• Skin disorder other than plaque psoriasis in affected area
• Previously immunized with any pneumococcal vaccine
• Subject has pustular or erythrodermic psoriasis
• Subject is immunocompromised
• Six or more herpes simplex virus outbreaks per year
• History or malignancy, chronic serious infection or hepatic disease

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — San Diego, California, United States
• Study site — New York, New York, United States
• Study site — New York, New York, United States
• Study site — Cleveland, Ohio, United States
• Study site — St. John's, Newfoundland and Labrador, Canada
• Study site — Markham, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.